文献速递遗传性与小管间质肾病

Lumasiran治疗原发性高草酸尿症1型的1/2期安慰剂对照随机试验

Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-05-13

这项首次人体、随机、安慰剂对照的1/2期研究评估了Lumasiran在健康成人和原发性高草酸尿症1型患者中的安全性、药代动力学和药效学。研究显示Lumasiran安全性可接受,无严重不良事件或导致停药的治疗相关事件,患者24小时尿草酸排泄平均最大降低75%,所有患者尿草酸水平达到正常上限的1.5倍及以下。

要点

  • Lumasiran安全性可接受,无严重不良事件或研究中止归因于治疗。
  • 患者24小时尿草酸排泄平均最大降低75%,所有患者尿草酸≤1.5倍正常上限。
  • 健康参与者中观察到平均血浆乙醇酸浓度升高,提示靶点结合。

核心结论

  • Lumasiran具有可接受的安全性,并使所有原发性高草酸尿症1型患者的尿草酸排泄降低至接近正常水平。

研究设计与样本

  • 1/2期随机安慰剂对照试验,A部分健康成人按3:1随机接受单次皮下Lumasiran或安慰剂(0.3-6 mg/kg递增剂量组)。
  • B部分原发性高草酸尿症1型患者按3:1随机接受最多三剂Lumasiran或安慰剂(1或3 mg/kg每月或3 mg/kg每季度),安慰剂组第85天交叉至Lumasiran。

主要发现

  • Lumasiran安全性可接受,无严重不良事件或研究中止归因于治疗。
  • A部分健康参与者中观察到平均血浆乙醇酸浓度升高。
  • B部分患者24小时尿草酸排泄较基线平均最大降低75%(跨剂量组)。
  • 所有患者达到尿草酸水平≤1.5倍正常上限。

临床怎么用

  • Lumasiran可用于原发性高草酸尿症1型患者,以降低尿草酸排泄至接近正常水平。
  • 治疗安全性可接受,未见严重不良事件或导致停药的治疗相关事件。

局限性

  • 数据采用描述性统计进行分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In the rare disease primary hyperoxaluria type 1, overproduction of oxalate by the liver causes kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production. The objective of this first-in-human, randomized, placebo-controlled trial was to evaluate the safety, pharmacokinetic, and pharmacodynamic profiles of lumasiran in healthy participants and patients with primary hyperoxaluria type 1. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This phase 1/2 study was conducted in two parts. In part A, healthy adults randomized 3:1 received a single subcutaneous dose of lumasiran or placebo in ascending dose groups (0.3-6 mg/kg). In part B, patients with primary hyperoxaluria type 1 randomized 3:1 received up to three doses of lumasiran or placebo in cohorts of 1 or 3 mg/kg monthly or 3 mg/kg quarterly. Patients initially assigned to placebo crossed over to lumasiran on day 85. The primary outcome was incidence of adverse events. Secondary outcomes included pharmacokinetic and pharmacodynamic parameters, including measures of oxalate in patients with primary hyperoxaluria type 1. Data were analyzed using descriptive statistics. RESULTS: Thirty-two healthy participants and 20 adult and pediatric patients with primary hyperoxaluria type 1 were enrolled. Lumasiran had an acceptable safety profile, with no serious adverse events or study discontinuations attributed to treatment. In part A, increases in mean plasma glycolate concentration, a measure of target engagement, were observed in healthy participants. In part B, patients with primary hyperoxaluria type 1 had a mean maximal reduction from baseline of 75% across dosing cohorts in 24-hour urinary oxalate excretion. All patients achieved urinary oxalate levels ≤1.5 times the upper limit of normal. CONCLUSIONS: Lumasiran had an acceptable safety profile and reduced urinary oxalate excretion in all patients with primary hyperoxaluria type 1 to near-normal levels. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Study of Lumasiran in Healthy Adults and Patients with Primary Hyperoxaluria Type 1, NCT02706886.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Frishberg Y, Deschênes G, Groothoff JW, et al. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Clin J Am Soc Nephrol. 2021. PMID: 33985991. doi:10.2215/CJN.14730920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。